CD7.CAR/28zeta CAR T cells

N/A

Report date: 2025/02/01 20:00:06

Base Information

Drug NameCD7.CAR/28zeta CAR T cells
Drug Alias NameCD7CAR-28-zeta CAR T-cell therapy (Baylor College of Medicine)Anti-CD7 CAR T-cell therapy (Baylor College of Medicine)Anti-CD7 CAR T-cell therapy (Baylor College of Medicine)
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapyBiologics > Protein drugs > Recombinant protein > Fusion protein
Mechanisms of ActionT-cell antigen CD7 modulators
TargetsT-cell antigen CD7
Therapy Area/IndicationsAngioimmunoblastic T-cell LymphomaLymphoma, T-Cell, PeripheralSezary Syndrome +[9] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesBaylor College Of Medicine
China Registration ClassN/A

Develop Information

Active CompaniesBaylor College Of Medicine
Inactive CompaniesN/A
Active IndicationsAngioimmunoblastic T-cell LymphomaLymphoma, T-Cell, PeripheralSezary Syndrome +[9] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A